HRT Financial’s Xeris Biopharma Holdings XERS Stock Holding History

HRT Financial’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$992K	Sell	171,102 -161,224	-49%	-$1.07M	﹤0.01%	2062
2025 Q4	$2.61M	Buy	332,326 +259,783	+358%	+$2.04M	0.01%	1130
2025 Q3	$590K	Buy	+72,543	New	+$482K	﹤0.01%	1799
2025 Q2	–	Sell	-81,112	Closed	-$445K	–	3636
2025 Q1	$445K	Buy	81,112 +60,440	+292%	+$244K	﹤0.01%	1530
2024 Q4	$70K	Buy	+20,672	New	+$66.5K	﹤0.01%	2080
2024 Q2	–	Sell	-182,324	Closed	-$402K	–	3228
2024 Q1	$402K	Buy	182,324 +94,990	+109%	+$246K	﹤0.01%	1377
2023 Q4	$205K	Buy	+87,334	New	+$161K	﹤0.01%	1785
2021 Q4	–	Sell	-10,435	Closed	-$25K	–	4201
2021 Q3	$25K	Sell	10,435 -80,080	-88%	-$233K	﹤0.01%	3128
2021 Q2	$368K	Buy	+90,515	New	+$345K	﹤0.01%	2011

Other funds holding XERS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HRT Financial's XERS Position: Q1 2026 in Review

HRT Financial reduced its Xeris Biopharma Holdings (XERS) stake by 49% in Q1 2026, selling an estimated $1.07M and leaving 171,102 shares worth $992K. The position accounts for ﹤0.01% of the portfolio, ranked #2062.

HRT Financial first reported a position in XERS in Q2 2021 and has held it in 9 quarters since. The position peaked at $2.61M in Q4 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

HRT Financial held 171,102 shares of Xeris Biopharma Holdings worth $992K as of Q1 2026.
HRT Financial sold 161,224 Xeris Biopharma Holdings shares in Q1 2026, an estimated $1.07M.
Xeris Biopharma Holdings made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #2062 holding.
HRT Financial first reported a position in Xeris Biopharma Holdings in Q2 2021 and has held it in 9 quarters since.
HRT Financial's Xeris Biopharma Holdings position peaked at $2.61M in Q4 2025.
237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.